Unknown

Dataset Information

0

Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.


ABSTRACT: PURPOSE:To evaluate patterns of primary prophylactic (PP) granulocyte colony-stimulating factor (G-CSF) use following chemotherapy by cancer type and febrile neutropenia (FN) risk. METHODS:Using a commercial administrative database, we identified adult patients diagnosed with breast, colorectal, lung, ovarian cancer, or non-Hodgkin lymphoma (NHL) who initiated chemotherapy with high risk (HR) or intermediate risk (IR) for FN between January 1, 2013, and August 31, 2017. We describe use of PP-G-CSF, proportion completing all their cycles with pegfilgrastim, timing of pegfilgrastim, and duration of short-acting G-CSF. RESULTS:Among 22,868 patients (breast 11,513; colorectal 3765; lung 4273; ovarian 1287; and NHL 2030), 36.8% received HR and 63.2% received IR (64.4% of whom had ??1 risk factor [RF] for FN). Proportions of patients receiving PP-G-CSF in the first cycle were 76.1%, 28.2%, and 26.4% among patients receiving HR, IR, and IR plus ??1 RF, respectively. Among breast cancer patients receiving HR regimens and initiating PP-pegfilgrastim, 60.4% (95% confidence interval [CI] 57.2-63.6%) initiating via on-body injector (OBI) and 51.9% (95% CI 48.0-55.8%) initiating via prefilled syringe (PFS) completed all their cycles with OBI and PFS, respectively. Among all cycles with PP-PFS, 8.5% received PFS on the same day as chemotherapy completion. Mean administrations/cycle were 3.2 (standard deviation [SD] 2.3) for filgrastim, 3.0 (SD 1.6) for filgrastim-sndz, and 4.3 (SD 2.5) for tbo-filgrastim. CONCLUSIONS:There is under- and mistimed use of PP-G-CSF among patients at HR for FN. Novel pegfilgrastim delivery devices could help breast cancer patients at HR for FN complete all their cycles with timely prophylaxis.

SUBMITTER: Gawade PL 

PROVIDER: S-EPMC7378111 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4584106 | BioStudies
2016-01-01 | S-EPMC4752449 | BioStudies
1000-01-01 | S-EPMC5357483 | BioStudies
2020-01-01 | S-EPMC7211191 | BioStudies
1000-01-01 | S-EPMC3559272 | BioStudies
2018-01-01 | S-EPMC6127997 | BioStudies
2020-01-01 | S-EPMC6954143 | BioStudies
2019-01-01 | S-EPMC6688232 | BioStudies
2019-01-01 | S-EPMC6420387 | BioStudies
1000-01-01 | S-EPMC6094503 | BioStudies